It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The regulation of thymocyte development by RNA-binding proteins (RBPs) is largely unexplored. We identify 642 RBPs in the thymus and focus on Arpp21, which shows selective and dynamic expression in early thymocytes. Arpp21 is downregulated in response to T cell receptor (TCR) and Ca2+ signals. Downregulation requires Stim1/Stim2 and CaMK4 expression and involves Arpp21 protein phosphorylation, polyubiquitination and proteasomal degradation. Arpp21 directly binds RNA through its R3H domain, with a preference for uridine-rich motifs, promoting the expression of target mRNAs. Analysis of the Arpp21–bound transcriptome reveals strong interactions with the Rag1 3′-UTR. Arpp21–deficient thymocytes show reduced Rag1 expression, delayed TCR rearrangement and a less diverse TCR repertoire. This phenotype is recapitulated in Rag1 3′-UTR mutant mice harboring a deletion of the Arpp21 response region. These findings show how thymocyte-specific Arpp21 promotes Rag1 expression to enable TCR repertoire diversity until signals from the TCR terminate Arpp21 and Rag1 activities.
Regulation of thymocyte development by RNA-binding proteins is not fully characterized. Here the authors show the RBP ARPP21 interacting with the Rag1 3’-UTR to promote Rag1 expression, TCR rearrangement and an increased diversity of the TCR repertoire and that ARPP21 is down regulated by TCR stimulation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
















1 Molecular Targets and Therapeutics Center, Helmholtz Zentrum München, Research Unit Molecular Immune Regulation, Munich, Germany (GRID:grid.4567.0) (ISNI:0000 0004 0483 2525); Huazhong University of Science and Technology, Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Wuhan, China (GRID:grid.33199.31) (ISNI:0000 0004 0368 7223)
2 Ludwig-Maximilians-Universität in Munich, Institute for Immunology, Biomedical Center (BMC), Faculty of Medicine, Planegg-Martinsried, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
3 Helmholtz Zentrum München, Institute of Structural Biology, Molecular Targets and Therapeutics Center, Neuherberg, Germany (GRID:grid.4567.0) (ISNI:0000 0004 0483 2525); Technical University of Munich, TUM School of Natural Sciences, Department of Bioscience and Bavarian NMR Center (BNMRZ), Garching, Germany (GRID:grid.6936.a) (ISNI:0000 0001 2322 2966)
4 Bioanalytical Mass Spectrometry, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany (GRID:grid.6936.a)
5 Molecular Targets and Therapeutics Center, Helmholtz Zentrum München, Research Unit Molecular Immune Regulation, Munich, Germany (GRID:grid.4567.0) (ISNI:0000 0004 0483 2525)
6 Helmholtz Zentrum München, Institute of Developmental Genetics, Neuherberg, Germany (GRID:grid.4567.0) (ISNI:0000 0004 0483 2525)
7 New York University, Grossman School of Medicine, Department of Pathology, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753)
8 Beth Israel Deaconess Medical Center, Harvard Medical School, Department of Medicine, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
9 Ludwig-Maximilians-Universität in Munich, Institute for Immunology, Biomedical Center (BMC), Faculty of Medicine, Planegg-Martinsried, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X); Boehringer Ingelheim Pharma GmbH & Co. KG, Cancer Immunology and Immune Modulation, Biberach an der Riss, Germany (GRID:grid.420061.1) (ISNI:0000 0001 2171 7500)
10 Faculty of Medicine, Ludwig-Maximilians-Universität in Munich, Institute for Molecular Biology, Biomedical Center (BMC), Planegg-Martinsried, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
11 German Research Center for Environmental Health, Monoclonal Antibody Core Facility, Neuherberg, Germany (GRID:grid.4567.0) (ISNI:0000 0004 0483 2525)
12 Helmholtz Diabetes Center at Helmholtz Zentrum München, Research Unit Type 1 Diabetes Immunology, Neuherberg, Germany (GRID:grid.4567.0) (ISNI:0000 0004 0483 2525); German Center for Diabetes Research (DZD), Neuherberg, Germany (GRID:grid.452622.5); Division of Clinical Pharmacology, Department of Medicine IV, Ludwig-Maximilians-Universität München, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
13 Ludwig-Maximilians-Universität in Munich, Max von Pettenkofer Institute, Faculty of Medicine, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
14 Institute of Molecular Biology (IMB), Mainz, Germany (GRID:grid.424631.6) (ISNI:0000 0004 1794 1771)
15 Helmholtz Zentrum München, Institute of Developmental Genetics, Neuherberg, Germany (GRID:grid.4567.0) (ISNI:0000 0004 0483 2525); Technical University of Munich, Chair of Developmental Genetics, Munich School of Life Sciences Weihenstephan, Freising, Germany (GRID:grid.6936.a) (ISNI:0000 0001 2322 2966); Munich Cluster of Systems Neurology (SyNergy), Munich, Germany (GRID:grid.452617.3); German Center for Neurodegenerative Diseases (DZNE) site Munich, Munich, Germany (GRID:grid.424247.3) (ISNI:0000 0004 0438 0426)
16 Bioanalytical Mass Spectrometry, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany (GRID:grid.424247.3); University Medical Center Göttingen, Department of Clinical Chemistry, Bioanalytics Group, Göttingen, Germany (GRID:grid.411984.1) (ISNI:0000 0001 0482 5331); Georg-August University Göttingen, Göttingen Center for Molecular Biosciences, Göttingen, Germany (GRID:grid.7450.6) (ISNI:0000 0001 2364 4210); University of Göttingen, Cluster of Excellence ‘Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells’ (MBExC), Göttingen, Germany (GRID:grid.7450.6) (ISNI:0000 0001 2364 4210)
17 ETH Zürich, Institute for Molecular Health Sciences, Zürich, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780); Repertoire Immune Medicines (Switzerland) AG, Schlieren, Switzerland (GRID:grid.5801.c)
18 Charite-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute for Integrative Neuroanatomie, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)
19 Molecular Targets and Therapeutics Center, Helmholtz Zentrum München, Research Unit Molecular Immune Regulation, Munich, Germany (GRID:grid.4567.0) (ISNI:0000 0004 0483 2525); University Medical Center Ulm, Department of Pediatrics and Adolescent Medicine, Ulm, Germany (GRID:grid.411984.1) (ISNI:0000 0001 0482 5331)
20 Molecular Targets and Therapeutics Center, Helmholtz Zentrum München, Research Unit Molecular Immune Regulation, Munich, Germany (GRID:grid.4567.0) (ISNI:0000 0004 0483 2525); Ludwig-Maximilians-Universität in Munich, Institute for Immunology, Biomedical Center (BMC), Faculty of Medicine, Planegg-Martinsried, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)